Further information

Use these valuable resources to further your understanding of Fresenius Kabi and biosimilars:



  • European Medicines Agency (EMA) – the EMA’s biosimilars website provides an overview of the EMA’s development standards and marketing authorization requirements for biosimilars
  • Medicines for Europe – representing the European generic, biosimilars and value-added pharmaceutical industries, the Medicines for Europe website provides information about industrial policy, regulatory and legal framework and key news
  • The International Generic and Biosimilar Medicines Association (IGBA) – an international network of generic medicines associations committed to promoting generic and biosimilar medicines, the IGBA’s website provides information about its principles and annual IGBA Conference  
  • Food and Drug Administration (FDA) – the US FDA’s biosimilars website provides an overview of biosimilars and the FDA’s licensure pathway for biosimilar products
  • Association for Accessible Medicines (AAM) – a trade association representing the manufacturers and distributors of generic prescription drugs, the AAM’s website provides information about its advocacy initiatives and events
  • Biosimilars Forum – a non-profit organization to advance biosimilars in the US, the Biosimilars Forum’s website provides research insights into biosimilars, as well as resources on policy and relevant news in the field


What makes Fresenius Kabi different? Learn here


FK/BIO/024/18 February 2019